ReviewVisceral medicine2017
Oligometastatic Disease in Upper Gastrointestinal Cancer - How to Proceed?
Review in Visceral medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Oligometastatic Gastric Cancer: Novel Considerations for Personalized Approach.Journal of gastrointestinal cancer · 2025Review
- Predictive factors for the detection of occult metastases during staging laparoscopy in patients with gastric carcinoma and adenocarcinoma of the esophagogastric junction.Langenbeck's archives of surgery · 2025Article
- Article
- Article
- State-of-the-art imaging in oesophago-gastric cancer.The British journal of radiology · 2022Review
- Surgery for Liver Metastasis of Non-Colorectal and Non-Neuroendocrine Tumors.Journal of clinical medicine · 2022Article
- Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.BMC surgery · 2021Article
- Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases.Scientific reports · 2020Article
- Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach.International journal of molecular sciences · 2020Review
- Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Review
- [Oligometastases in gastric and esophageal cancer : Current clinical trials and surgical concepts].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2018Review
- [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2018Review
- [Therapeutic approach in oligometastatic gastric and esophageal cancer].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2017Review
- Oligometastases of Gastrointestinal Cancer Origin.Visceral medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the present study we review and discuss the current evidence and suggest how to proceed in the management of oligometastatic disease in upper gastrointestinal cancer.
methodsAn electronic search of the PubMed database for relevant articles was performed.
resultsBoth the search for 'oligometastasis', 'oligometastases', 'oligometastatic', 'oligometastatic disease' as well as 'esophageal' and 'esophageal cancer' and the search for 'oligometastasis', 'oligometastases', 'oligometastatic', 'oligometastatic disease' as well as 'gastric', 'gastric cancer', 'stomach', and 'stomach cancer' yielded very few studies. Most data need to be extrapolated in general studies on oligometastatic diseases of different origins. No randomized controlled trial could be found.
conclusionIn the absence of data to formulate recommendations on how to proceed in the treatment of oligometastatic disease in upper gastrointestinal cancer, a more aggressive treatment of oligometastatic disease can be considered in patients whose tumors show a more favorable neoplastic behavior after the 'test of time'. The RENAISSANCE study will certainly deliver important data regarding this aspect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.